View Older Stories View More Recent Stories

Feb 20, 2024 09:25AM Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
Feb 20, 2024 07:00AM RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
Feb 12, 2024 08:32AM Gilead Sciences (GILD) to Acquire CymaBay Therapeutics (CBAY) for $32.50 Per Share, $4.3 Billion
Feb 12, 2024 08:30AM Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Feb 9, 2024 11:00AM Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
Jan 29, 2024 05:01PM Gilead Sciences (GILD), Arcus (RCUS) Announce Amended Collaboration and $320M Equity Investment
Jan 29, 2024 05:00PM Gilead and Arcus Announce Amended Collaboration and Equity Investment
Jan 23, 2024 04:05PM Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
Jan 3, 2024 11:15AM Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
Dec 21, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 20, 2023 08:45AM RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Dec 19, 2023 07:01AM Gilead Sciences (GILD) and Compugen (CGEN) Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Dec 19, 2023 07:00AM Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Dec 11, 2023 12:00PM Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
Nov 15, 2023 06:00AM Kite (GILD) and Arcellx (ACLX) Expand Strategic Partnership
Nov 15, 2023 06:00AM Kite and Arcellx Announce Expansion in Strategic Partnership
Nov 15, 2023 06:00AM ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
Nov 14, 2023 08:45AM Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
Nov 8, 2023 07:13PM Gilead Sciences to Present at Upcoming Investor Conferences
Nov 3, 2023 11:00AM Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
Oct 31, 2023 07:31AM Gilead Sciences' (GILD) Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
Oct 31, 2023 07:30AM Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
Oct 24, 2023 12:00PM Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
Oct 20, 2023 05:13AM Gilead Sciences (GILD) Presents New Data Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca
Oct 20, 2023 05:10AM New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
Oct 19, 2023 03:00AM Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
Oct 17, 2023 07:00AM Gilead Sciences (GILD) and Assembly Biosciences (ASMB) Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
Oct 17, 2023 07:00AM Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
Oct 16, 2023 01:01AM Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
Oct 12, 2023 04:05PM Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
Oct 3, 2023 08:30AM Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Oct 2, 2023 09:00AM Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
Sep 19, 2023 08:32AM Gilead Sciences (GILD) Announces CHMP Adopts Positive Opinion to Extend the Use of Veklury to Treat COVID-19 in People With Hepatic Impairment
Sep 19, 2023 08:30AM CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
Aug 24, 2023 08:30AM Gilead Sciences (GILD) Announces FDA Approval of Veklur to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Aug 24, 2023 08:30AM FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
Aug 23, 2023 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Aug 21, 2023 08:30AM Gilead Sciences (GILD) Announces Partial Clinical Hold for Magrolimab Studies in AML
Aug 21, 2023 08:30AM Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
Aug 18, 2023 12:00PM Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
Aug 15, 2023 08:33AM Gilead Sciences (GILD) and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
Aug 15, 2023 08:30AM Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Aug 2, 2023 01:55PM Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
Jul 27, 2023 01:29PM Gilead Sciences (GILD) Announces EU Approval of Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jul 27, 2023 01:23PM European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
Jul 25, 2023 05:39AM Gilead Sciences (GILD) Reports Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Jul 24, 2023 07:00PM Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
Jul 24, 2023 06:07AM Gilead Sciences (GILD) To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
Jul 23, 2023 09:51PM New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
View More Recent Stories View Older Stories